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ABSTRACT
Introduction: HbA1c is the gold standard for
glycemic control in pre-diabetes and diabetes.
However, its validity has been questioned,
especially in the presence of imbalanced iron
homeostasis. The CLEVER trial aims to evaluate
the relationship between iron deficiency and
HbA1c (a biomarker for the diagnosis and
therapeutic monitoring of type 2 diabetes) in a
randomized, placebo-controlled, multicenter
clinical trial.
Methods: The CLEVER (intravenous ferric Car-
boxymaLtosE for improVement of mEtabolic
parameters in type 2 diabetes patients with iRon
deficiency) trial is a randomized, single-blind,
proof-of-concept study with two treatment
arms. 140 men and women diagnosed with type
2 diabetes and iron deficiency will receive either
placebo or ferric carboxymaltose (500 or
1000 mg) as intravenous infusions. The primary
outcome measure is the change in HbA1c level
between baseline and after 12 weeks of treat-
ment. Secondary endpoints include change of
iron status and metabolic markers as well as
treatment safety and tolerability. Furthermore,
the potential clinical improvement in quality of
life and the reliability of HbA1c measurement in
patients with type 2 diabetes and iron defi-
ciency will be investigated.
Results: Both excessive iron and iron deficiency
are associated with metabolic disorders; exces-
sive iron is a risk factor for the development of
diabetes, whereas iron deficiency is associated
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with obesity and insulin resistance. It has been
suggested that iron increases insulin secretion
in pancreatic beta-cells. CLEVER is the first
study to investigate the hypothesis that intra-
venous substitution with ferric carboxymaltose
reduces HbA1c levels in patients with type 2
diabetes and iron deficiency, thereby improving
metabolic status and quality of life.
Clinical Trial Registration: ClinicalTrials.gov
(NCT01513369).
Funding: GWT-TUD GmbH acts as sponsor of
the clinical trial. Financial support is provided
by Vifor Pharma.
Keywords: Ferinject; Ferric carboxymaltose;
HbA1c; Intravenous; Iron deficiency; Type 2
diabetes mellitus
INTRODUCTION
Iron influences glucose metabolism, and the
link between iron metabolism and diabetes is
well established [1, 2]. The relationship is bidi-
rectional: iron affects glucose metabolism, and
glucose metabolism interferes with several iron
metabolic pathways. Whereas excessive iron
seems to be involved in the pathogenesis of
diabetes, iron deficiency has been linked with
obesity and insulin resistance. However, the
crosstalk between iron and energy metabolism
as well as pathophysiological processes such as
inflammation, peripheral ischemia, and
hypoxia is still not fully understood [3].
Although the HbA1c value is well established
as a biomarker for the diagnosis of diabetes and
for monitoring the treatment of diabetes, its
reliability, especially under conditions of an
altered iron homeostasis, has been challenged.
HbA1c levels appear to be affected by iron sta-
tus, as several studies have demonstrated
increased values under conditions of iron
depletion and iron deficiency anemia (IDA) in
both type 1 diabetic and nondiabetic popula-
tions [4–7]. On the other hand, iron substitu-
tion therapy results in a significant drop in
HbA1c values [5–7]. There is evidence that
iron-associated elevations and reductions in
HbA1c do not properly reflect glycemic status,
resulting in a spuriously exaggerated number of
people that are diagnosed with pre-diabetes and
diabetes and overtreatment when HbA1c is used
as the primary indicator for glycemic control
[8–10].
The hypothesis to be tested in the CLEVER
trial is that infusion of ferric carboxymaltose
(FCM) in patients with type 2 diabetes (T2DM)
and iron deficiency (ID) significantly reduces
HbA1c, as has already been shown for other
populations, e.g., nondiabetic people and
patients with type 1 diabetes. The reliability of
HbA1c as an indicator for glycemic control will
be assessed by the concomitant determination
of fasting blood glucose and fructosamine.
Moreover, the treatment of ID and metabolic
status improvement are expected to have an
impact on the overall quality of life, which will
be evaluated as a secondary endpoint.
METHODS
Study Design
The CLEVER trial is designed as a multicenter,
randomized, single-blind, proof-of-concept
study. Men and women with T2DM and ID are
randomized 1:1 to treatment with either FCM
or placebo (0.9% NaCl solution) administered as
an intravenous drip infusion over 30 min. The
aim of the study is to investigate a systematic
influence of ID on HbA1c. Participants will also
be monitored for the occurrence of treat-
ment-emergent adverse events and overall
health status. After confirming eligibility at the
screening visit (V1a), participants will enter the
treatment phase, consisting of three visits. At
visit 1b, baseline data for iron and metabolic
status and quality of life will be recorded, and
the first dose of the study medication will be
administered. FCM (Ferinject, Vifor Pharma
Deutschland GmbH) will be dosed at 500 or
1000 mg, depending on the individual body
weight and hemoglobin level (Fig. 1). This will
be followed by an observation period of 30 min
to monitor the tolerability of the infusion. Iron
status will be assessed based on the following
laboratory parameters: ferritin, transferrin,
transferrin saturation (TSAT), soluble transferrin
receptor (sTFR), serum iron, hemoglobin, mean
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corpuscular volume, mean corpuscular hemo-
globin, % hypochromic cells, reticulocyte
hemoglobin content, and hepcidin. HbA1c,
fasting blood glucose, and fructosamine as well
as the insulin dosage used will serve as markers
to assess the metabolic status. Overall health
status and quality of life (QoL) will be evaluated
by the Euro-QoL (EQ5D) questionnaire. In
accordance with the summary of product char-
acteristics (SmPC) and the study protocol, par-
ticipants will receive a second dose of study
medication at visit 2a, which is scheduled for
4 weeks after the first dose. In cases where iron
deficiency persists, a third dose will be admin-
istered approximately 5 days after the second
dosing (visit 2b). Finally, primary and secondary
outcome parameters will be assessed at the
end-of-study visit scheduled for 8 weeks after
the application of the final dose of study med-
ication. The visit schedule, including study-re-
lated actions/measures, is shown in Table 1.
This trial is registered under the US National
Institutes of Health ClinicalTrials.gov identifier
NCT01513369. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human experimen-
tation (institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
Study Population
Men and women 18 years or older and diag-
nosed with T2DM as well as ID (defined as
serum ferritin\150 ng/mL or transferrin satu-
ration\25% if hemoglobin\14 g/dL; or serum
ferritin\100 ng/mL or transferrin satura-
tion\20% if hemoglobin C 14 g/dL and B 15 g/
dL) are eligible for inclusion in the CLEVER
trial. HbA1c values between 48 and
69 mmol/mol (6.5% and 8.5%) were defined for
inclusion in the study based on data from
El-Agouza et al. [7], who showed that HbA1c
values of nondiabetic people treated with iron
were reduced from 6.15% ± 0.62% to
5.25% ± 0.45%. Consequently, it was hypothe-
sized that people with T2DM will demonstrate a
Fig. 1 CLEVER study design. #Deﬁned as
HbA1c C 48 mmol/mol (6.5%) and\69 mmol/mol
(8.5%). ##Deﬁned as serum ferritin\150 ng/mL or
transferrin saturation\25% if hemoglobin\14 g/dL or
serum ferritin\100 ng/mL or transferrin satura-
tion\20% if hemoglobin C 14 g/dL and B 15 g/dL.
*Control parameter: ferritin and transferrin saturation.
**If still iron deﬁcient at V2a [serum ferritin\150 ng/mL
or transferrin saturation\25%], an additional dose of
500 mg ferric carboxymaltose is given at V2b, otherwise it
is not
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similar response. A detailed list of inclusion and
exclusion criteria is given in Table 2.
The protocol will be conducted in accor-
dance with the Declaration of Helsinki and
good clinical practice guidelines and approved
by each center’s institutional ethics review
board. Informed consent for inclusion in the
study will be obtained from all patients.
Study Objectives
The primary aim of the study is to confirm that
HbA1c levels are reduced after iron repletion
therapy in people with ID and T2DM, as has
already been reported for different populations
such as healthy subjects, pregnant women, or
patients with type 1 diabetes [5, 6, 11]. More-
over, the interrelationships of iron treatment
and the subsequent reduction in HbA1c with
selected parameters of overall health status and
glucose metabolism will be assessed in more
detail. For this purpose, changes in primary and
secondary endpoints between baseline and
12 weeks after the start of intravenous iron
repletion therapy will be evaluated. A full list of
primary and secondary endpoints is presented
in Table 3.
Sample Size Calculation
The study will be conducted as a single-blind,
randomized, controlled, hypothesis-generating
pilot study. Originally, a systematic statistical
case number calculation was performed. The
estimated reduction in HbA1c due to iron sub-
stitution in type 1 diabetes patients reported in
the published literature is - 2.3% [5]. Calculat-
ing with a power of 80%, an alpha of 0.05, and
Table 1 Visit schedule and study-related actions/measures
Visit 1a 1b 2a (2b)* 3
Week 0
Day 0
Screening
Week 1
Day 7 –
5 days
Baseline
Week 5
– 14 days
Week 5
– 14 days
1 5 days
Week 13
– 14 days
End of study
Informed consent 4
Inclusion/exclusion criteria 4
Demographic data 4
Height, weight, BMI, waist circumference 4
Anamnesis/medical history 4
Urine pregnancy test 4
Concomitant medication 4 4 4 (4) 4
Randomization 4
Vital signs (blood pressure, pulse, body temperature) 4 4 4 (4) 4
Laboratory 4 4 4
Study drug administration 4 4 (4)
Adverse event and serious adverse event 4 4 (4) 4
Documentation of used insulin and blood glucose 4 4 4
Euro-QoL (EQ5D) questionnaire 4 4 4
* If still iron deﬁcient [serum ferritin\150 ng/mL or ferritin saturation\25%], an additional visit (visit 2b) for
administration of 500 mg ferric carboxymaltose is necessary, otherwise it is not
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an expected HbA1c difference due to intra-
venous iron substitution in the present study of
0.7% ± 1.4%, a total of n = 126 participants
(63 per treatment arm) must be included in the
CLEVER trial in order to reach statistical signif-
icance. Assuming a 20% expected dropout rate,
this sample size would need to be increased to
152 participants, i.e., 76 per treatment group.
However, if the dropout rate is only 10%, 70
patients per treatment arm will be sufficient to
reach statistical significance. An interim analy-
sis is planned in order to re-evaluate the validity
of the hypothesis for the HbA1c difference
between the two treatment arms after 64
patients (32 patients per arm) have completed
the study. This interim analysis will follow the
three zones method described by Mehta and
Pocock [12] using the Lan–DeMets procedure
and an O’Brien–Fleming spending function.
The final number of participants to be included
will be adjusted during the study depending on
the dropout rate and results from the interim
analysis.
Table 2 Key inclusion and exclusion criteria
Key inclusion
criteria
Men and women older than 18 years
Diagnosis of type 2 diabetes and iron deﬁciency deﬁned as follows:
HbA1c C 48 mmol/mol (6.5%) and\69 mmol/mol (8.5%)
Serum ferritin\150 ng/mL or transferrin saturation\25% if hemoglobin\14 g/dL
Serum ferritin\100 ng/mL or transferrin saturation\20% if hemoglobin C 14 g/dL and B 15 g/dL
Key exclusion
criteria
Continuous subcutaneous insulin infusion
Thalassemia
Hemoglobin[15 g/dL (C 9.31 mmol/L)
C-reactive protein[15 mg/L
Change in HbA1c of more than ± 0.3% within the last 3 months
Hypersensitivity to the active substance, to Ferinject, or to any of its excipients
Known serious hypersensitivity to other parenteral iron products
History of acquired iron overload
History of erythropoietin-stimulating agent, IV or high-dose oral iron therapy or blood
transfusion\12 weeks prior to randomization
Body weight B 40 kg
Chronic or active liver disease
Vitamin B12 and/or serum folate deﬁciency
Current malignancy under treatment
Renal function GFR\30 mL/min/1.73 m2
Signiﬁcant major cardiovascular disease ongoing or in the past 3 months
Polyneuropathy without ischemia
Pregnant or nursing (lactating) women
Any person not willing to use adequate contraceptive precautions during the study and for up to 5 days
after the last scheduled dose of study medication
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Statistical Methods
Continuous variables will be checked for nor-
mality using the Kolmogorov–Smirnov test, and
non-normally distributed variables will be
log-transformed before analysis. If no normal
distribution is obtained, the Mann–Whitney
U test will be used instead of a t test. A summary
of baseline data (demographic, anamnestic
data, and laboratory parameters) will be pro-
vided. The compilation will involve a compar-
ison of mean values, indicating the
corresponding standard deviations, as well as t
tests between the treatment arms. For nominal
variables, the frequency will be counted and
tested using the chi-square test to check for
significant differences between treatment
groups.
Changes in primary and secondary parame-
ters between baseline and the end of the study
will be tested using a paired t test or a Wilcoxon
rank sum test for each treatment arm and using
an independent t test for the last visit between
treatment arms. A boxplot or confidence inter-
val plot will be presented. If the baseline values
of HbA1c are significantly different between the
treatment groups, an analysis of covariance
(ANCOVA) for HbA1c at the last visit will be
needed. A linear model will be searched for
using stepwise regression (forward and back-
ward selection) with all independent variables
at the beginning of the selection.
All nominal and categorical variables will be
summarized descriptively with the following
parameters: number of observations and abso-
lute and relative frequencies based on the
number of observations. Continuous and ordi-
nal variables will be summarized by means of
number of observations, arithmetic mean,
standard deviation, median, p5, p25, p75, and
p95 percentiles, and the minimum and maxi-
mum. Correlations will be calculated using
Pearson correlation coefficients.
The statistical analysis of primary and sec-
ondary endpoints will be done on the per-pro-
tocol set, which includes all participants who
are randomized and treated according to the
protocol. Safety parameters will be listed for all
participants who received at least one dose of
study medication.
DISCUSSION
Roughly one-third of the general population is
affected by ID, which is one of the most com-
mon nutritional deficiencies worldwide [13]. ID
designates a reduction in storage iron (as shown
by reduced serum ferritin and confirmed by
decreased bone marrow iron staining) as well as
decreased utilizable iron (represented by
reduced transferrin saturation values), which
indicates the amount of immediately available
iron. Several chronic disorders such as rheu-
matic disease, metabolic syndrome, coronary
artery disease, and chronic liver disease are
confounded by alterations in iron homeostasis
[14–17], and correcting ID may impact mor-
bidity, mortality, and quality of life in these
patients. Iron deficiency anemia (IDA) is a
Table 3 Study endpoints
Primary
endpoint
Change in HbA1c from baseline to the
end of the study
Secondary
endpoints
Change in iron status from baseline to
the end of the study as measured by
hemoglobin, mean corpuscular volume,
mean corpuscular hemoglobin, %
hypochromic cells, reticulocyte
hemoglobin content, ferritin,
transferrin, transferrin saturation
(TSAT), soluble transferrin receptor
(sTFR), serum iron, hepcidin
Change in metabolic status from baseline
to the end of the study as measured by
fasting blood glucose and fructosamine
Change in insulin dosage used per
application from baseline to the end of
the study
Reliability of HbA1c measurements
Change in quality of life from baseline to
the end of treatment as assessed by
Euro-QoL (EQ5D) questionnaire
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global public health burden and appears to be
more common in people with diabetes than in
the nondiabetic population. IDA negatively
affects glycemic control. Thus, correcting IDA
can be expected to improve diabetes control
and prevent disease-related complications [18].
The bidirectional relationship between iron
metabolism and glucose homeostasis is
increasingly being recognized. A relative iron
excess appears to affect metabolic processes
such as insulin action and secretion. Conse-
quently, ensuring balanced body iron stores
may be a promising therapeutic target for peo-
ple suffering from T2DM as well as for those at
risk of developing T2DM [2]. In a population of
883 subjects with no known history of diabetes,
Shimodaira et al. [19] demonstrated that serum
iron levels were not associated with insulin
resistance or b-cell function. However, it was
speculated that insulin secretion was negatively
affected by higher hemoglobin levels.
HbA1c, the major form of glycated hemo-
globin, was incorporated into a monitoring
program for individuals with diabetes in 1976,
and is now the gold standard for glycemic
control. In healthy people, HbA1c reaches a
steady state at 3.0%–6.5% (9–48 mmol/mol) of
the overall body hemoglobin, while the HbA1c
fraction is abnormally elevated in patients with
chronic hyperglycemia and is positively corre-
lated with glycemic control. However, certain
conditions such as genetic variants that alter
HbA1c through nonglycemic pathways may
affect its validity as marker for glycemic control
[20]. Furthermore, the reliability of HbA1c as a
biomarker for the diagnosis of diabetes and for
monitoring treatment in patients with diabetes
suffering from imbalanced iron homeostasis is
being questioned, as iron depletion spuriously
increases HbA1c values—there is no corre-
sponding change in blood glucose [10]. Raja-
gopal [4] as well as Silva [21] and coworkers
demonstrated a statistically significant differ-
ence in HbA1c values between cases of mild,
moderate, and severe IDA, even in nondiabetic
individuals. On the other hand, a significant
drop in HbA1c with iron substitution therapy
has been observed in various populations,
including people with no history of diabetes
and people with type 1 diabetes (see Table 4).
Table 4 Studies demonstrating a decrease in HbA1c after iron substitution therapy (HbA1c values are given as mean ± SD
or [95% conﬁdence interval])
Reference Population n HbA1c before
treatment
HbA1c after
treatment
Difference in
mean HbA1c
Treatment
Davis
1983
[30]
68-year-old woman
with IDA and DM
1 10.7% (without
IDA)
15.4%
(with IDA)
11% 4.4% Not disclosed
Tarim
1999 [5]
Patients with type 1
DM and ID
11 10.6% ± 2.6% 8.3% ± 2.6% 2.3%
(P\0.05)
Oral 6 mg/kg/day for
3 months
Tarim
1999 [5]
Nondiabetic patients
with ID
11 7.7% ± 1.3% 6.4% ± 1.2% 1.3%
(P\0.05)
Oral 6 mg/kg/day for
3 months
El-Agouza
2002 [7]
Students with IDA 51 6.15% ± 0.62% 5.25% ± 0.45% 0.9%
(P\0.001)
Oral ferrous sulphate
325 mg/day for 20 weeks
Coban
2004 [6]
Nondiabetic patients
with IDA
50 7.4% ± 0.8% 6.2% ± 0.6% 1.2%
(P\0.001)
Oral 100 mg/day for
3 months
Ng 2010
[22]
Patients with type 2
DM and chronic
kidney disease
15 7.40%
[6.60–8.19]
6.96%
[6.27–7.25]
0.4%
(P\0.001)
Single dose of low
molecular weight iron
dextran as IV infusion
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Notably, the only study that investigated the
effect of iron supplementation in a population
with T2DM included patients who additionally
suffered from chronic kidney disease. As such,
this study was also able to demonstrate that
intravenous iron caused a significant decrease
in HbA1c values without any change in gly-
cemic control in patients who primarily had
T2DM and ID [22].
In the literature, several hypotheses for the
increase in HbA1c under iron-depleted condi-
tions have been discussed. Brooks et al. [23]
proposed that the quaternary structure of the
hemoglobin molecule is altered in ID, which
may result in more rapid glycosylation of the b
chain. Other scientists have argued that condi-
tions affecting erythrocyte turnover may also
influence HbA1c concentrations, and have
suggested that the rise in HbA1c may be a result
of reduced cell production in IDA, leading to an
extended lifespan of circulating erythrocytes
[24]. Studies by El-Agouza et al. [7] and Coban
et al. [6] demonstrated elevated levels of HbA1c
in IDA patients which significantly decreased
after iron substitution therapy. They postulated
that under conditions of IDA, the decreased
hemoglobin concentration would result in an
increased glycated fraction if the serum glucose
remained constant.
Interestingly, a series of other studies inves-
tigating the effect of IDA on HbA1c draw a
contradictory picture, as they revealed a
decreased HbA1c at baseline and a subsequent
rise with iron supplementation, or no difference
between IDA and nonanemic populations
[25–27].
Although this topic has been addressed by
many groups within the last decade, and a
couple of hypotheses have been proposed, there
is still no sufficiently proven explanation that
supports any of these hypotheses in particular,
and so further studies are warranted to shed
more light on the relationship between ID and
HbA1c. However, there is a general consensus
that abnormalities in erythrocyte indices are a
considerable confounder in the analysis of
HbA1c, and there is currently insufficient data
to guide physicians in everyday clinical prac-
tice. Therefore, English et al. [28] elaborated a
couple of recommendations to consider in
addition to the published guidance. For the
time being, implementing these rules would
prevent the misdiagnosis of diabetes in people
with ID who are in the threshold range of
HbA1c, as well as the overtreatment of
well-adjusted people with diabetes who develop
ID and would, in the worst case scenario, end
up with a high risk of hypoglycemia.
The investigator-initiated CLEVER trial is
designed to evaluate if people with T2DM profit
from intravenous iron therapy with FCM.
Recently, HbA1c [6.5% (48 mmol/mol) has
been introduced as the cutoff limit for newly
diagnosed diabetes. This level of HbA1c control
is recommended by national and international
guidelines. Thus, falsely high measured levels of
HbA1c due to ID would lead to overtreatment,
with potentially high risks of hypoglycemia and
weight gain in known diabetics who receive
insulin treatment. This underscores that valid
HbA1c values are particularly important in
people under strict glucose control. Correcting
ID is presumed to improve glucose status in
these patients and may additionally have a
positive clinical impact on vascular function in
patients with T2DM on oral antidiabetic com-
bination therapy. Many people with diabetes
already have an impaired quality of life and ID
constitutes an additional burden. A reduced
hemoglobin level also identifies diabetics who
are at an increased risk of adverse outcomes,
independent of the presence or severity of
nephropathy.
In the present study, reconstitution or at
least an improvement in iron homeostasis will
be achieved by intravenous infusion of FCM,
which has greater bioavailability and compli-
ance and was demonstrated to be more effective
and (due to its lack of gastrointestinal intoler-
ance) better tolerated than oral iron [29]. Thus,
the study will also provide important data about
the pharmacodynamics of ferric carboxymal-
tose and address the question of whether data
attained after intravenous iron substitution
therapy are comparable to those obtained after
oral dosing, as well as checking the timeframe
required to achieve a clinically measurable
improvement. A series of parameters for the
characterization of easily available iron and iron
stores will be evaluated along with parameters
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of glycemic status. HbA1c will serve as the pri-
mary endpoint, in line with many clinical
studies that investigate the effects of new med-
ications as potential novel treatments for dia-
betes. However, other markers for glycemic
control, such as fasting blood glucose, fruc-
tosamine, and administered insulin dosage, will
be determined along with HbA1c concentra-
tions to prove the reliability of this indicator.
Furthermore, treatment-emergent adverse
events and the quality of life of each study
participant will be monitored. Finally, the
clinical results obtained from the CLEVER trial
will provide further scientific insight into the
relationship between iron and metabolic status
as well as its clinical relevance.
CONCLUSION
The aim of the CLEVER trial is to further
investigate the link between ID, intravenous
iron substitution, and HbA1c (the most clini-
cally relevant biomarker used for diagnosing
and treating type 2 diabetes as a widespread
disease). It is hypothesized that intravenous
substitution with FCM significantly reduces
HbA1c in people with ID and T2DM, thereby
improving metabolic status and quality of life.
Conversely, this would mean that people suf-
fering from ID might be misdiagnosed with
diabetes. Moreover, if a diagnosis of T2DM has
already been made and therapeutic control is
achieved by relying on HbA1c values, patients
suffering from ID are potentially overtreated,
leading to a significant risk of hypoglycemic
episodes. Consequently, the role of HbA1c as a
biomarker for diagnosing and treating diabetes
would likely need to be reconsidered, and
changes in/restrictions on the interpretation of
HbA1c values in ID patients would have to be
implemented in national and international
diabetes guidelines.
The results of the CLEVER trial will presum-
ably support the use of intravenous FCM in
clinical practice, especially in people suffering
from diabetes and ID. As HbA1c evaluation is a
cornerstone of diabetes management, it is also
necessary from a drug safety point of view to
critically demonstrate the validity of HbA1c as
the most important clinical biomarker for
monitoring diabetes therapy by performing a
randomized, controlled study of a population
suffering from T2DM during drug therapy with
FCM, which has been shown to significantly
influence and bias this parameter.
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